Mind Medicine (NASDAQ: MNMD) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% ...

周二，专注于迷幻药研究的生物科技公司Mind ...

Mescaline is under clinical development by Mind Medicine MindMed and currently in Phase I for Unspecified Psychiatric Disorders.

Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase I for Pain.

Robert Barrow, the Chief Executive Officer of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), a $502 million market cap company that has delivered an impressive 108% return... Mark Sullivan ...

Osteopathy is a medical field that takes a holistic approach to the treatment of illness and injury. Considered a form of ...

After hours: 7:44:27 p.m. EST ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Check out the trailer for the half-hour animated sci-fi series 'Common Side Effects,' premiering Feb. 2 on Adult Swim. The ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel ...